70817-17-3

Usage

Uses

Used in Pharmaceutical Industry:
(1-Benzyl-1H-pyrazol-4-yl)methanol is used as a building block for the synthesis of various pharmaceuticals due to its unique chemical structure and properties. It has been shown to exhibit biological activity, including anti-inflammatory and antimicrobial properties, making it a promising candidate for the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, (1-Benzyl-1H-pyrazol-4-yl)methanol is used as a building block for the synthesis of various agrochemicals. Its unique chemical structure and properties allow it to be incorporated into compounds that can be used in the development of new pesticides, herbicides, and other agricultural products.
Used in Materials Industry:
(1-Benzyl-1H-pyrazol-4-yl)methanol also has potential applications in the materials industry. Its unique chemical structure and properties make it a valuable component in the development of new materials with specific properties, such as improved strength, durability, or resistance to certain conditions.
Overall, (1-Benzyl-1H-pyrazol-4-yl)methanol is a versatile compound with potential uses in both the pharmaceutical and materials industries, as well as in agrochemical development. Its unique properties and applications make it a valuable asset in the ongoing pursuit of innovation and advancement in these fields.

Upstream product

• 100-39-0 benzyl bromide 
• 861135-90-2 methyl 1-benzylpyrazole-4-carboxylate 
• 150559-94-7 ethyl 1‐benzyl‐1H‐pyrazole‐4‐carboxylate 

Downstream Products

• 861135-54-8 1-benzyl-4-(chloromethyl)-1H-pyrazole hydrochloride 
• 63874-95-3 1-benzyl-1H-pyrazole-4carboxaldehyde 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE

The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).

Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer

SUMOylation is a reversible post-translational modification that regulates protein function through covalent attachment of small ubiquitin-like modifier (SUMO) proteins. The process of SUMOylating proteins involves an enzymatic cascade, the first step of which entails the activation of a SUMO protein through an ATP-dependent process catalyzed by SUMO-activating enzyme (SAE). Here, we describe the identification of TAK-981, a mechanism-based inhibitor of SAE which forms a SUMO-TAK-981 adduct as the inhibitory species within the enzyme catalytic site. Optimization of selectivity against related enzymes as well as enhancement of mean residence time of the adduct were critical to the identification of compounds with potent cellular pathway inhibition and ultimately a prolonged pharmacodynamic effect and efficacy in preclinical tumor models, culminating in the identification of the clinical molecule TAK-981.

FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE

This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O?X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.

A2B ADENOSINE RECEPTOR ANTAGONISTS

Disclosed are novel compounds that are A2B adenosine receptor antagonists having the following structure (I) wherein R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.

MALONONITRILE COMPOUND AS PESTICIDES

The present invention provides a malononitrile compound represented by the formula (I): wherein any one of X1, X2, X3 and X4 is CR100, wherein R100 is a group represented by the formula: the other three of X1, X2, X3 and X4 each represent nitrogen or CR5, provided that 1 to 3 of X1, X2, X3 and X4 represent nitrogen, and Z represents oxygen, sulfur or NR6, which has pest-controlling activity.

Insecticidal pyrazole-4-methanol esters

Compounds of the formula STR1 wherein R is phenyl, benzyl, 1-isopropylbenzyl wherein each of said aromatic rings may carry a chlorine substituent, STR2 R' is H, --C N or --C CH; R" is chlorine, bromine, fluorine or methyl; X and Y both but independently are H or loweralkyl; and Z is phenyl or benzyl which may carry an optional aromatic chlorine substituent, have been found to be excellent insecticides, ovicides and/or miticides.